Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 5/2015

01-05-2015 | Genitourinary Infections (J Sobel, Section Editor)

Rituximab Causing Deep Ulcerative Suppurative Vaginitis/Pyoderma Gangrenosum

Authors: Priya Selva-Nayagam, Gayle Fischer, Ian Hamann, Jack Sobel, Craig James

Published in: Current Infectious Disease Reports | Issue 5/2015

Login to get access

Abstract

Pyoderma gangrenosum (PG) is a rare cause of purulent vulvovaginal ulceration. Six recent cases of vulvovaginal pyoderma gangrenosum associated with rituximab are described. All cases were seen in the setting of rituximab used for the treatment of B cell non Hodgkin’s lymphoma (NHL). Age range was 50–74; symptoms were present for 2–24 months and severe pain, heavy discharge and large, deep purulent ulcers extending into the vagina were seen. This article reviews previous reports of vulvovaginal pyoderma gangrenosum, discusses important differential diagnoses in this setting, and provides evidence supporting rituximab as the cause of pyoderma gangrenosum in this cohort.
Literature
1.
2.
Satoh M, Yamamoto T. Genital pyoderma gangrenosum: report of two cases and published work review of Japanese cases. J Dermatol. 2013;40(10):840–3.PubMed
3.
Hadi A, Lebwohl M. Clinical features of pyoderma gangrenosum and current diagnostic trends. J Am Acad Dermatol. 2011;64(5):950–4.CrossRefPubMed
4.
Dixit S, Selva-Nayagam P, Hamann I, Fischer G. Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy. J Low Genit Tract Dis 2014.
5.
Walsh M, Leonard N, Bell H. Superficial granulomatous pyoderma of the vulva in a patient receiving maintenance rituximab (mabthera) for lymphoma. J Low Genit Tract Dis. 2011;15(2):158–60.CrossRefPubMed
6.
Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106–11.CrossRefPubMedCentralPubMed
7.
Tsuboi H. Case of pyoderma gangrenosum showing oral and genital ulcers, misdiagnosed as Behcet’s disease at first medical examination. J Dermatol. 2008;35(5):289–92.CrossRefPubMed
8.
Reed BG, Shippey S, Kremp A, Belin E. Vulvar pyoderma gangrenosum originating from a healed obstetric laceration. Obstet Gynecol. 2013;122(2 Pt 2):452–5.CrossRefPubMed
9.
Roé E, Dalmau J, García-Navarro X, Corella F, Monfort D, Busquets D, et al. A case of vulvar pyoderma gangrenosum associated with collagenous colitis. Dermatology. 2006;213(3):234–5.CrossRefPubMed
10.
Valmadre S, Gee A, Dalrymple C. Pyoderma gangrenosum of the vulva. Aust N Z J Obstet Gynaecol. 2002;42(5):548–9.CrossRefPubMed
11.
Sau M, Hill NC. Pyoderma gangrenosum of the vulva. BJOG. 2001;108(11):1197–8.PubMed
12.
Borum ML, Cannava M, Myrie-Williams C. Refractory, disfiguring vulvar pyoderma gangrenosum and Crohn’s disease. Dig Dis Sci. 1998;43(4):720–2.CrossRefPubMed
13.
Garcovich S, Gatto A, Ferrara P, Garcovich A. Vulvar pyoderma gangrenosum in a child. Pediatr Dermatol. 2009;26(5):629–31.CrossRefPubMed
14.
Langeland T, Rokkones E. Pyoderma gangrenosum as a cause of spontaneous vulvovaginal ulceration. Acta Obstet Gynecol Scand. 2004;83(12):1220–1.CrossRefPubMed
15.
Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191–211.CrossRefPubMed
16.
Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800.CrossRefPubMed
17.
Lehman JS, Bruce AJ, Wetter DA, Ferguson SB, Rogers RS. Reactive nonsexually related acute genital ulcers: review of cases evaluated at mayo clinic. J Am Acad Dermatol. 2010;63(1):44–51.CrossRefPubMed
18.
Dixit S, Bradford J, Fischer G. Management of nonsexually acquired genital ulceration using oral and topical corticosteroids followed by doxycycline prophylaxis. J Am Acad Dermatol. 2013;68(5):797–802.CrossRefPubMed
19.
Curtis C, Douglas I. Pyoderma gangrenosum in a syringe driver site of a patient with non-Hodgkin’s lymphoma. Palliat Med. 2006;20(2):113–4.CrossRefPubMed
20.
Pereira N, Brites MM, Gonçalo M, Tellechea O, Figueiredo A. Pyoderma gangrenosum—a review of 24 cases observed over 10 years. Int J Dermatol. 2013;52(8):938–45.CrossRefPubMed
21.
Miall FM, Harman K, Kennedy B, Dyer MJ. Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin’s lymphoma. Br J Haematol. 2006;132(1):115–6.CrossRefPubMed
22.
Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro) myelocyte stage of granulopoiesis. Med Oncol. 2008;25(4):374–9.CrossRefPubMed
23.
Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635–42.CrossRefPubMed
24.
Nakagawa T, Natsume A, Satoh M, Niwa R. Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophils. Leuk Res. 2010;34(5):666–71.CrossRefPubMed
25.
26.
Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venereol. 2010;90(2):183–5.CrossRefPubMed
27.
Braun-Falco M, Ruzicka T. Skin manifestations in autoinflammatory syndromes. J Dtsch Dermatol Ges. 2011;9(3):232–46.PubMed
28.
Marzano AV, Fanoni D, Antiga E, Quaglino P, Caproni M, Crosti C, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178:48–56.CrossRefPubMed
29.
Guenova E, Teske A, Fehrenbacher B, Hoerber S, Adamczyk A, Schaller M, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147(10):1203–5.CrossRefPubMed
Metadata
Title
Rituximab Causing Deep Ulcerative Suppurative Vaginitis/Pyoderma Gangrenosum
Authors
Priya Selva-Nayagam
Gayle Fischer
Ian Hamann
Jack Sobel
Craig James
Publication date
01-05-2015
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 5/2015
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-015-0478-5

Other articles of this Issue 5/2015

Current Infectious Disease Reports 5/2015 Go to the issue

Pediatric Infectious Diseases (I Brook, Section Editor)

Acute Otitis Media in Children—Current Treatment and Prevention

Tropical, Travel and Emerging Infections (L Chen, Section Editor)

Ebola Virus Disease: History, Epidemiology and Outbreaks

Pediatric Infectious Diseases (I Brook, Section Editor)

Challenges in the Management of Acute Mastoiditis in Children

Genitourinary Infections (J Sobel, Section Editor)

Selecting Anti-Microbial Treatment of Aerobic Vaginitis

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Infectious Complications of Pancreatic Islet Transplantation: Clinical Experience and Unanswered Questions

Central Nervous System Infections (J Lyons, Section Editor)

Neurosyphilis Update: Atypical is the New Typical
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits